Base de dados : MEDLINE
Pesquisa : E02.095.160.570 [Categoria DeCS]
Referências encontradas : 3241 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 325 ir para página                         

  1 / 3241 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453759
[Au] Autor:Eberhardson M; Karlén P; Linton L; Jones P; Lindberg A; Kostalla MJ; Lindh E; Odén A; Glise H; Winqvist O
[Ad] Endereço:Department of Gastroenterology, Karolinska University Hospital, Karolinska Institutet, Stockholm, Sweden.
[Ti] Título:Randomised, Double-blind, Placebo-controlled Trial of CCR9-targeted Leukapheresis Treatment of Ulcerative Colitis Patients.
[So] Source:J Crohns Colitis;11(5):534-542, 2017 May 01.
[Is] ISSN:1876-4479
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background and Aims: Ulcerative colitis patients display increased numbers of circulating pro-inflammatory monocyte human leukocyte antigen-DR [HLA-DRhi] monocytes expressing high levels of the gut-homing C-C chemokine receptor 9 [CCR9] and tumour necrosis factor [TNF]-α. The aim of this first-in-human, double-blind, randomised, placebo-controlled trial was to evaluate selective removal of circulating CCR9-expressing monocytes by leukapheresis in patients with moderate to severe ulcerative colitis, with regards to safety, tolerability, and immunological response. Methods: Patients with ulcerative colitis were treated every second day with leukapheresis during five sessions with a C-C chemokine ligand 25 [CCL25; CCR9 ligand] column or a placebo column. Results: No major safety concerns were raised and the procedure was well tolerated. Pro-inflammatory HLA-DRhi cells decreased significantly in the active treatment group [p = 0.0391] whereas no statistically significant change was seen in the placebo group [p = 0.4688]. There was a significant decrease of HLA-DRhi monocytes in the active group compared with the placebo group when corrected for the imbalance in weight between the groups [p = 0.0105]. Mayo score decreased in the active group [p = 0.0156] whereas the change in the placebo group was not significant [p = 0.1250]. Mayo score ≤ 3 was observed in five out of 14 patients [35.7%] in the active group compared with one out of eight [12.5%] receiving placebo. The number of responders in the active treatment group was eight out of 14 patients [57.1%], whereas in the corresponding placebo group three out of eight patients [37.5%] responded to placebo. A dose-response correlation was observed between the blood volume processed and clinical outcome. Conclusion: This clinical induction trial using CCL25-tailored leukapheresis demonstrates a safe and effective removal of activated monocytes with a clinical effect in patients with ulcerative colitis.
[Mh] Termos MeSH primário: Colite Ulcerativa/terapia
Leucaférese/métodos
Receptores CCR/metabolismo
[Mh] Termos MeSH secundário: Adulto
Método Duplo-Cego
Feminino
Citometria de Fluxo
Seres Humanos
Masculino
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE; RANDOMIZED CONTROLLED TRIAL
[Nm] Nome de substância:
0 (CC chemokine receptor 9); 0 (Receptors, CCR)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1093/ecco-jcc/jjw196


  2 / 3241 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28715249
[Au] Autor:Turtle CJ; Hay KA; Hanafi LA; Li D; Cherian S; Chen X; Wood B; Lozanski A; Byrd JC; Heimfeld S; Riddell SR; Maloney DG
[Ad] Endereço:Cameron J. Turtle, Kevin A. Hay, Laïla-Aïcha Hanafi, Shelly Heimfeld, Stanley R. Riddell, and David G. Maloney, Fred Hutchinson Cancer Research Center; Cameron J. Turtle, Sindhu Cherian, Xueyan Chen, Brent Wood, Stanley R. Riddell, and David G. Maloney, University of Washington; Daniel Li, Juno Ther
[Ti] Título:Durable Molecular Remissions in Chronic Lymphocytic Leukemia Treated With CD19-Specific Chimeric Antigen Receptor-Modified T Cells After Failure of Ibrutinib.
[So] Source:J Clin Oncol;35(26):3010-3020, 2017 Sep 10.
[Is] ISSN:1527-7755
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Purpose We evaluated the safety and feasibility of anti-CD19 chimeric antigen receptor-modified T (CAR-T) cell therapy in patients with chronic lymphocytic leukemia (CLL) who had previously received ibrutinib. Methods Twenty-four patients with CLL received lymphodepleting chemotherapy and anti-CD19 CAR-T cells at one of three dose levels (2 × 10 , 2 × 10 , or 2 × 10 CAR-T cells/kg). Nineteen patients experienced disease progression while receiving ibrutinib, three were ibrutinib intolerant, and two did not experience progression while receiving ibrutinib. Six patients were venetoclax refractory, and 23 had a complex karyotype and/or 17p deletion. Results Four weeks after CAR-T cell infusion, the overall response rate (complete response [CR] and/or partial response [PR]) by International Workshop on Chronic Lymphocytic Leukemia (IWCLL) criteria was 71% (17 of 24). Twenty patients (83%) developed cytokine release syndrome, and eight (33%) developed neurotoxicity, which was reversible in all but one patient with a fatal outcome. Twenty of 24 patients received cyclophosphamide and fludarabine lymphodepletion and CD19 CAR-T cells at or below the maximum tolerated dose (≤ 2 × 10 CAR-T cells/kg). In 19 of these patients who were restaged, the overall response rate by IWCLL imaging criteria 4 weeks after infusion was 74% (CR, 4/19, 21%; PR, 10/19, 53%), and 15/17 patients (88%) with marrow disease before CAR-T cells had no disease by flow cytometry after CAR-T cells. Twelve of these patients underwent deep IGH sequencing, and seven (58%) had no malignant IGH sequences detected in marrow. Absence of the malignant IGH clone in marrow of patients with CLL who responded by IWCLL criteria was associated with 100% progression-free survival and overall survival (median 6.6 months follow-up) after CAR-T cell immunotherapy. The progression-free survival was similar in patients with lymph node PR or CR by IWCLL criteria. Conclusion CD19 CAR-T cells are highly effective in high-risk patients with CLL after they experience treatment failure with ibrutinib therapy.
[Mh] Termos MeSH primário: Imunoterapia Adotiva/métodos
Leucemia Linfocítica Crônica de Células B/terapia
Pirazóis/administração & dosagem
Pirimidinas/administração & dosagem
Receptores de Antígenos de Linfócitos T/imunologia
Linfócitos T/imunologia
Linfócitos T/transplante
[Mh] Termos MeSH secundário: Adulto
Idoso
Antígenos CD19/imunologia
Intervalo Livre de Doença
Seres Humanos
Imunoterapia Adotiva/efeitos adversos
Leucaférese/métodos
Leucemia Linfocítica Crônica de Células B/tratamento farmacológico
Leucemia Linfocítica Crônica de Células B/imunologia
Depleção Linfocítica/métodos
Meia-Idade
Pirazóis/efeitos adversos
Pirimidinas/efeitos adversos
Indução de Remissão
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE I; CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, CD19); 0 (CD19 molecule, human); 0 (CD19-specific chimeric antigen receptor); 0 (PCI 32765); 0 (Pyrazoles); 0 (Pyrimidines); 0 (Receptors, Antigen, T-Cell)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170922
[Lr] Data última revisão:
170922
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170718
[St] Status:MEDLINE
[do] DOI:10.1200/JCO.2017.72.8519


  3 / 3241 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28653421
[Au] Autor:Lisenko K; Baertsch MA; Meiser R; Pavel P; Bruckner T; Kriegsmann M; Schmitt A; Witzens-Harig M; Ho AD; Hillengass J; Wuchter P
[Ad] Endereço:Department of Medicine V, Heidelberg University, Heidelberg, Germany.
[Ti] Título:Comparison of biosimilar filgrastim, originator filgrastim, and lenograstim for autologous stem cell mobilization in patients with multiple myeloma.
[So] Source:Transfusion;57(10):2359-2365, 2017 Oct.
[Is] ISSN:1537-2995
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Granulocyte-colony-stimulating factor (G-CSF) originators such as filgrastim (Neupogen) and lenograstim (Granocyte) are widely used for peripheral blood stem cell (PBSC) mobilization. In recent years, biosimilar agents have been approved for the same indications. The aim of this retrospective study was to compare the mobilization efficiency of the three G-CSF variants originator filgrastim, lenograstim, and the biosimilar Filgrastim Hexal in a homogeneous group of multiple myeloma (MM) patients in first-line therapy. STUDY DESIGN AND METHODS: Overall mobilization data of 250 patients with MM were included. Of these patients, 74 (30%), 131 (52%), and 45 (18%) were mobilized with originator filgrastim, biosimilar Filgrastim Hexal, or lenograstim, respectively, at a dose of 5 to 10 µg/kg body weight subcutaneously starting from Day 5 after chemomobilization with CAD (cyclophosphamide, doxorubicin, dexamethasone) until completion of PBSC collection. RESULTS: All but one patient reached the collection goal of a minimum of at least 2 × 10 CD34+ cells/kg body weight during a median of one (range, one to three) leukapheresis session. No significant differences in CD34+ mobilization and collection yields between the filgrastim-mobilized (median, 10.5; range, 2.7-40.4), Filgrastim Hexal-mobilized (median, 9.9; range, 0.2-26.0), and lenograstim-mobilized (median, 10.7; range, 3.1-27.9 CD34+ cells × 10 /kg body weight) patients were observed. CONCLUSION: Concerning the clinically relevant efficiencies of PBSC mobilization and in terms of reaching the individual collection target, this retrospective study did not detect any significant differences between the three G-CSF variants in the analyzed patient cohort.
[Mh] Termos MeSH primário: Medicamentos Biossimilares/normas
Mobilização de Células-Tronco Hematopoéticas/métodos
Mieloma Múltiplo/terapia
[Mh] Termos MeSH secundário: Adulto
Idoso
Antígenos CD34/análise
Medicamentos Biossimilares/uso terapêutico
Feminino
Filgrastim/normas
Filgrastim/uso terapêutico
Fator Estimulador de Colônias de Granulócitos/normas
Fator Estimulador de Colônias de Granulócitos/uso terapêutico
Mobilização de Células-Tronco Hematopoéticas/normas
Seres Humanos
Leucaférese
Masculino
Meia-Idade
Proteínas Recombinantes/normas
Proteínas Recombinantes/uso terapêutico
Estudos Retrospectivos
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, CD34); 0 (Biosimilar Pharmaceuticals); 0 (Recombinant Proteins); 143011-72-7 (Granulocyte Colony-Stimulating Factor); 6WS4C399GB (lenograstim); PVI5M0M1GW (Filgrastim)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170628
[St] Status:MEDLINE
[do] DOI:10.1111/trf.14211


  4 / 3241 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28629733
[Au] Autor:Yin Y; Bai Y; Olivera A; Desai A; Metcalfe DD
[Ad] Endereço:Laboratory of Allergic Diseases, National Institute of Allergy and Infectious Diseases,National Institutes of Health, Bethesda, MD 20892, USA. Electronic address: yiny@niaid.nih.gov.
[Ti] Título:An optimized protocol for the generation and functional analysis of human mast cells from CD34 enriched cell populations.
[So] Source:J Immunol Methods;448:105-111, 2017 Sep.
[Is] ISSN:1872-7905
[Cp] País de publicação:Netherlands
[La] Idioma:eng
[Ab] Resumo:The culture of mast cells from human tissues such a cord blood, peripheral blood or bone marrow aspirates has advanced our understanding of human mast cells (huMC) degranulation, mediator production and response to pharmacologic agents. However, existing methods for huMC culture tend to be laborious and expensive. Combining technical approaches from several of these protocols, we designed a simplified and more cost effective approach to the culture of mast cells from human cell populations including peripheral blood and cryopreserved cells from lymphocytapheresis. On average, we reduced by 30-50 fold the amount of culture media compared to our previously reported method, while the total MC number generated by this method (2.46±0.63×10 vs. 2.4±0.28×10 , respectively, from 1.0×10 lymphocytapheresis or peripheral blood mononuclear blood cells [PBMCs]) was similar to our previous method (2.36±0.70×10 ), resulting in significant budgetary savings. In addition, we compared the yield of huMCs with or without IL-3 added to early cultures in the presence of stem cell factor (SCF) and interlukin-6 (IL-6) and found that the total MC number generated, while higher with IL-3 in the culture, did not reach statistical significance, suggesting that IL-3, often recommended in the culture of huMCs, is not absolutely required. We then performed a functional analysis by flow cytometry using standard methods and which maximized the data we could obtain from cultured cells. We believe these approaches will allow more laboratories to culture and examine huMC behavior going forward.
[Mh] Termos MeSH primário: Antígenos CD34/metabolismo
Separação Celular/métodos
Leucaférese
Mastócitos/metabolismo
Células-Tronco/metabolismo
[Mh] Termos MeSH secundário: Antígenos CD34/imunologia
Biomarcadores/metabolismo
Orçamentos
Degranulação Celular
Diferenciação Celular
Linhagem da Célula
Proliferação Celular
Separação Celular/economia
Forma Celular
Células Cultivadas
Redução de Custos
Análise Custo-Benefício
Criopreservação
Meios de Cultura/metabolismo
Citometria de Fluxo
Seres Humanos
Interleucina-3/farmacologia
Interleucina-6/farmacologia
Leucaférese/economia
Mastócitos/efeitos dos fármacos
Mastócitos/imunologia
Fenótipo
Proteínas Proto-Oncogênicas c-kit/metabolismo
Receptores de IgE/metabolismo
Fator de Células-Tronco/farmacologia
Células-Tronco/efeitos dos fármacos
Células-Tronco/imunologia
Fatores de Tempo
Fluxo de Trabalho
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, CD34); 0 (Biomarkers); 0 (Culture Media); 0 (IL3 protein, human); 0 (IL6 protein, human); 0 (Interleukin-3); 0 (Interleukin-6); 0 (Receptors, IgE); 0 (Stem Cell Factor); EC 2.7.10.1 (Proto-Oncogene Proteins c-kit)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171026
[Lr] Data última revisão:
171026
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170621
[St] Status:MEDLINE


  5 / 3241 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28592046
[Au] Autor:Liu ZF; Zheng HH; Jiang XL
[Ti] Título:[The application of selectie granulocyte and monocyte apheresis in the treatment of ulcerative colitis].
[So] Source:Zhonghua Nei Ke Za Zhi;56(6):444-446, 2017 Jun 01.
[Is] ISSN:0578-1426
[Cp] País de publicação:China
[La] Idioma:chi
[Mh] Termos MeSH primário: Colite Ulcerativa/terapia
Granulócitos
Leucaférese/métodos
Monócitos
[Mh] Termos MeSH secundário: Adulto
Remoção de Componentes Sanguíneos
Feminino
Seres Humanos
Masculino
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170904
[Lr] Data última revisão:
170904
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170609
[St] Status:MEDLINE
[do] DOI:10.3760/cma.j.issn.0578-1426.2017.06.012


  6 / 3241 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28432476
[Au] Autor:Sáez-González E; Moret I; Alvarez-Sotomayor D; Díaz-Jaime FC; Cerrillo E; Iborra M; Nos P; Beltrán B
[Ad] Endereço:Gastroenterology Department, La Fe University and Polytechnic Hospital, Avenida Fernando Abril Martorell 106, 46020, Valencia, Spain. esteban.digestivo@gmail.com.
[Ti] Título:Immunological Mechanisms of Adsorptive Cytapheresis in Inflammatory Bowel Disease.
[So] Source:Dig Dis Sci;62(6):1417-1425, 2017 Jun.
[Is] ISSN:1573-2568
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Ulcerative colitis and Crohn's disease are the two main forms of inflammatory bowel disease (IBD). The study of immunological pathways involved in the onset of IBD is of fundamental importance to identify potential biological markers of disease activity and specific targets for therapy. Removing excess and activated circulating leukocytes with adsorptive cytapheresis has been shown to be a potentially effective treatment for patients with an inflamed bowel. Adsorptive cytapheresis is a non-pharmacological approach for active IBD, in which known sources of inflammatory cytokines such as activated myeloid lineage leucocytes are selectively depleted from the circulatory system. The decrease in inflammatory load caused by removing these cells is thought to enhance drug therapy and thereby promote disease remission. The benefit of cytapheresis appears to rest upon its ability to reduce levels of certain immune cell populations; however, whether this depletion results in further changes in lymphocyte populations and cytokine production needs further clarification. In this review, we aim to summarize existing evidence on the role of cytapheresis in patients with IBD, its effect on cytokine levels and cellular populations, and to discuss its potential impact on disease activity.
[Mh] Termos MeSH primário: Citocinas/sangue
Doenças Inflamatórias Intestinais/imunologia
Doenças Inflamatórias Intestinais/terapia
Leucaférese/métodos
[Mh] Termos MeSH secundário: Adsorção
Granulócitos
Seres Humanos
Imunoterapia
Leucaférese/instrumentação
Monócitos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Cytokines)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170423
[St] Status:MEDLINE
[do] DOI:10.1007/s10620-017-4577-z


  7 / 3241 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28411378
[Au] Autor:Khoury HJ; Collins RH; Blum W; Stiff PS; Elias L; Lebkowski JS; Reddy A; Nishimoto KP; Sen D; Wirth ED; Case CC; DiPersio JF
[Ad] Endereço:Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, Georgia.
[Ti] Título:Immune responses and long-term disease recurrence status after telomerase-based dendritic cell immunotherapy in patients with acute myeloid leukemia.
[So] Source:Cancer;123(16):3061-3072, 2017 Aug 15.
[Is] ISSN:1097-0142
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Telomerase activity in leukemic blasts frequently is increased among patients with high-risk acute myeloid leukemia (AML). In the current study, the authors evaluated the feasibility, safety, immunogenicity, and therapeutic potential of human telomerase reverse transcriptase (hTERT)-expressing autologous dendritic cells (hTERT-DCs) in adult patients with AML. METHODS: hTERT-DCs were produced from patient-specific leukapheresis, electroporated with an mRNA-encoding hTERT and a lysosomal-targeting sequence, and cryopreserved. A total of 22 patients with a median age of 58 years (range, 30-75 years) with intermediate-risk or high-risk AML in first or second complete remission (CR) were enrolled. hTERT-DCs were generated for 24 patients (73%). A median of 17 intradermal vaccinations (range, 6-32 intradermal vaccinations) containing 1×10 cells were administered as 6 weekly injections followed by 6 biweekly injections. A total of 21 patients (16 in first CR, 3 in second CR, and 2 with early disease recurrence) received hTERT-DCs. RESULTS: hTERT-DCs were well tolerated with no severe toxicities reported, with the exception of 1 patient who developed idiopathic thrombocytopenic purpura. Of the 19 patients receiving hTERT-DCs in CR, 11 patients (58%) developed hTERT-specific T-cell responses that primarily were targeted toward hTERT peptides with predicted low human leukocyte antigen (HLA)-binding affinities. With a median follow-up of 52 months, 58% of patients in CR (11 of 19 patients) were free of disease recurrence at the time of their last follow-up visit; 57% of the patients who were aged ≥60 years (4 of 7 patients) also were found to be free of disease recurrence at a median follow-up of 54 months. CONCLUSIONS: The generation of hTERT-DCs is feasible and vaccination with hTERT-DCs appears to be safe and may be associated with favorable recurrence-free survival. Cancer 2017;123:3061-72. © 2017 American Cancer Society.
[Mh] Termos MeSH primário: Vacinas Anticâncer/uso terapêutico
Células Dendríticas/metabolismo
Imunoterapia/métodos
Leucaférese
Leucemia Mieloide Aguda/terapia
Telomerase/genética
[Mh] Termos MeSH secundário: Adulto
Idoso
Intervalo Livre de Doença
ELISPOT
Estudos de Viabilidade
Feminino
Seres Humanos
Leucemia Mieloide Aguda/imunologia
Masculino
Meia-Idade
RNA Mensageiro
Indução de Remissão
Linfócitos T/imunologia
[Pt] Tipo de publicação:CLINICAL TRIAL, PHASE II; JOURNAL ARTICLE; MULTICENTER STUDY
[Nm] Nome de substância:
0 (Cancer Vaccines); 0 (RNA, Messenger); EC 2.7.7.49 (TERT protein, human); EC 2.7.7.49 (Telomerase)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170911
[Lr] Data última revisão:
170911
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170416
[St] Status:MEDLINE
[do] DOI:10.1002/cncr.30696


  8 / 3241 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28373606
[Au] Autor:Yamamoto A; Hashimoto K; Yamasaki A; Takata M; Morita M; Funaki Y; Okada K; Teruya Y; Fukushima T; Shimizu E
[Ad] Endereço:Division of Medical Oncology and Molecular Respirology, Department of Multidisciplinary Internal Medicine, Faculty of Medicine, Tottori University.
[Ti] Título:Leukocytapheresis for the treatment of acute exacerbation of idiopathic interstitial pneumonias: a pilot study.
[So] Source:J Med Invest;64(1.2):110-116, 2017.
[Is] ISSN:1349-6867
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Idiopathic interstitial pneumonias (IIPs) are a group of heterogeneous diffuse parenchymal lung disorders of unknown etiology. An acute exacerbation (AE) is an acute respiratory deterioration that occurs in IIPs. The prognosis of AE of IIPs (AE-IIPs) is extremely severe; however, no established therapies exist. We aimed to evaluate the efficacy of leukocytapheresis (LCAP) to treat patients with AE-IIPs. PATIENTS AND METHODS: Six chronic IIPs patients who developed AE were enrolled in this study. We performed LCAP on days 2, 3, 9 and 10 in all six patients. All patients were also treated with high-dose corticosteroids and a continuous administration of low-molecular-weight heparin. We observed 30-day survival after the diagnosis of AE to evaluate the efficacy of LCAP. We also assessed oxygenation, high-resolution computed tomography (HRCT) findings, and certain chemical mediators in the peripheral blood. RESULTS: Five of six patients survived more than 30 days. One patient died of progressive respiratory failure. Oxygenation and HRCT findings tended to improve in all survivors. The serum levels of lactate dehydrogenase, high mobility group box-1, and interleukin-18 were significantly decreased statistically post-LCAP. No severe adverse events occurred. CONCLUSION: We suggest that LCAP is a safe and effective therapy for treating patients with AE-IIPs. J. Med. Invest. 64: 110-116, February, 2017.
[Mh] Termos MeSH primário: Pneumonias Intersticiais Idiopáticas/terapia
Leucaférese
[Mh] Termos MeSH secundário: Doença Aguda
Idoso
Idoso de 80 Anos ou mais
Feminino
Seres Humanos
Pneumonias Intersticiais Idiopáticas/sangue
Pneumonias Intersticiais Idiopáticas/diagnóstico por imagem
Fibrose Pulmonar Idiopática/terapia
Mediadores da Inflamação/sangue
Masculino
Projetos Piloto
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Inflammation Mediators)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171031
[Lr] Data última revisão:
171031
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170405
[St] Status:MEDLINE
[do] DOI:10.2152/jmi.64.110


  9 / 3241 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28368400
[Au] Autor:Madapura HS; Nagy N; Ujvari D; Kallas T; Kröhnke MCL; Amu S; Björkholm M; Stenke L; Mandal PK; McMurray JS; Keszei M; Westerberg LS; Cheng H; Xue F; Klein G; Klein E; Salamon D
[Ad] Endereço:Department of Microbiology, Tumor and Cell Biology, Karolinska Institutet, Stockholm, Sweden.
[Ti] Título:Interferon γ is a STAT1-dependent direct inducer of BCL6 expression in imatinib-treated chronic myeloid leukemia cells.
[So] Source:Oncogene;36(32):4619-4628, 2017 Aug 10.
[Is] ISSN:1476-5594
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:B-cell CLL/lymphoma 6 (BCL6) exerts oncogenic effects in several human hematopoietic malignancies including chronic myeloid leukemia (CML), where BCL6 expression was shown to be essential for CML stem cell survival and self-renewal during imatinib mesylate (IM) treatment. As several lines of evidence suggest that interferon γ (IFNγ) production in CML patients might have a central role in the response to tyrosine kinase inhibitor (TKI) therapy, we analyzed if IFNγ modulates BCL6 expression in CML cells. Although separate IFNγ or IM treatment only slightly upregulated BCL6 expression, combined treatment induced remarkable BCL6 upregulation in CML lines and primary human CD34+ CML stem cells. We proved that during combined treatment, inhibition of constitutive signal transducer and activator of transcription (STAT) 5 activation by IM allowed the specific enhancement of the STAT1 dependent, direct upregulation of BCL6 by IFNγ in CML cells. By using colony-forming assay, we found that IFNγ enhanced the ex vivo colony or cluster-forming capacity of human CML stem cells in the absence or presence of IM, respectively. Furthermore, inhibition of the transcriptional repressor function of BCL6 in the presence of IM and IFNγ almost completely blocked the cluster formation of human CML stem cells. On the other hand, by using small interfering RNA knockdown of BCL6, we demonstrated that in an IM-treated CML line the antiapoptotic effect of IFNγ was independent of BCL6 upregulation. We found that IFNγ also upregulated several antiapoptotic members of the BCL2 and BIRC gene families in CML cells, including the long isoform of MCL1, which proved to be essential for the antiapoptotic effect of IFNγ in an IM-treated CML line. Our results suggest that combination of TKIs with BCL6 and MCL1 inhibitors may potentially lead to the complete eradication of CML stem cells.
[Mh] Termos MeSH primário: Mesilato de Imatinib/uso terapêutico
Interferon gama/uso terapêutico
Leucemia Mieloide de Fase Crônica/tratamento farmacológico
Proteínas Proto-Oncogênicas/metabolismo
Proteínas Repressoras/metabolismo
Fator de Transcrição STAT1/metabolismo
[Mh] Termos MeSH secundário: Antígenos CD34/metabolismo
Linhagem Celular Tumoral
Seres Humanos
Mesilato de Imatinib/farmacologia
Interferon gama/farmacologia
Leucaférese
Leucemia Mieloide de Fase Crônica/metabolismo
Proteína de Sequência 1 de Leucemia de Células Mieloides/metabolismo
Células-Tronco Neoplásicas/efeitos dos fármacos
Proteína Inibidora de Apoptose Neuronal/efeitos dos fármacos
Proteína Inibidora de Apoptose Neuronal/metabolismo
Proteínas Proto-Oncogênicas/genética
RNA Interferente Pequeno/genética
RNA Interferente Pequeno/metabolismo
Proteínas Repressoras/genética
Fator de Transcrição STAT1/genética
Fator de Transcrição STAT5/genética
Fator de Transcrição STAT5/metabolismo
Proteína de Morte Celular Associada a bcl/efeitos dos fármacos
Proteína de Morte Celular Associada a bcl/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, CD34); 0 (BCOR protein, human); 0 (MCL1 protein, human); 0 (Myeloid Cell Leukemia Sequence 1 Protein); 0 (NAIP protein, human); 0 (Neuronal Apoptosis-Inhibitory Protein); 0 (Proto-Oncogene Proteins); 0 (RNA, Small Interfering); 0 (Repressor Proteins); 0 (STAT1 Transcription Factor); 0 (STAT1 protein, human); 0 (STAT5 Transcription Factor); 0 (bcl-Associated Death Protein); 82115-62-6 (Interferon-gamma); 8A1O1M485B (Imatinib Mesylate)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170926
[Lr] Data última revisão:
170926
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170404
[St] Status:MEDLINE
[do] DOI:10.1038/onc.2017.85


  10 / 3241 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28331129
[Au] Autor:Tanaka H; Ishii A; Sugita Y; Shimizu R; Sato F; Sakuma Y; Iwai R; Kakuta S
[Ad] Endereço:Department of Hematology, Asahi General Hospital.
[Ti] Título:Impact of Hematopoietic Progenitor Cell Count as an Indicator for Optimal Timing of Peripheral Stem Cell Harvest in Clinical Practice.
[So] Source:J Clin Exp Hematop;56(3):150-159, 2017.
[Is] ISSN:1880-9952
[Cp] País de publicação:Japan
[La] Idioma:eng
[Ab] Resumo:For optimizing CD34+ cell collection, appropriately timing peripheral blood stem cell harvest (PBSCH) initiation is crucial. Automatic cell analyzers with the immature myeloid information channel provide hematopoietic progenitor cell (HPC) count, a surrogate marker of CD34+ cells, which can be obtained within a few minutes without requiring monoclonal antibodies. The final decision on PBSCH initiation can be made using the HPC count obtained on the morning of the harvest day. Herein, we evaluated the impact of the HPC count as an indicator for the optimal timing of PBSCH in clinical practice over 9 years. One hundred and eighteen aphereses from 72 cases had a definite number of CD34+ cells/kg in the PBSC yield. A correlation was found between the HPC count in the PB and the CD34+ cell count (R = 0.563, p < 0.001), whereas no correlation existed between the white blood cell and CD34+ cell counts (R = 0.0418, p = 0.65). We defined > 2.0 × 10 /kg of CD34+ cells in a single apheresis as good mobilization. Multivariate analysis demonstrated that an HPC count of > 21/µL, myeloblast count of > 12/µL, and age at PBSCH of < 50 years were independently associated with good mobilization (p = 0.001, p < 0.001, and p = 0.005, respectively). Our findings suggest that the HPC count is a good indicator for the optimal timing of PBSCH.
[Mh] Termos MeSH primário: Antígenos CD34/análise
Mobilização de Células-Tronco Hematopoéticas/métodos
Células-Tronco Hematopoéticas/citologia
Células-Tronco de Sangue Periférico/citologia
[Mh] Termos MeSH secundário: Adulto
Feminino
Mobilização de Células-Tronco Hematopoéticas/normas
Seres Humanos
Leucaférese/métodos
Leucaférese/normas
Contagem de Leucócitos
Masculino
Meia-Idade
Transplante de Células-Tronco de Sangue Periférico/métodos
Padrões de Prática Médica/normas
Fatores de Tempo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, CD34)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170410
[Lr] Data última revisão:
170410
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170324
[St] Status:MEDLINE
[do] DOI:10.3960/jslrt.56.150



página 1 de 325 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde